285 related articles for article (PubMed ID: 37452860)
21. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
22. Evolution of precision oncology-guided treatment paradigms.
DasGupta R; Yap A; Yaqing EY; Chia S
WIREs Mech Dis; 2023 Jan; 15(1):e1585. PubMed ID: 36168283
[TBL] [Abstract][Full Text] [Related]
23. Challenging issues in pediatric oncology.
Pui CH; Gajjar AJ; Kane JR; Qaddoumi IA; Pappo AS
Nat Rev Clin Oncol; 2011 Jun; 8(9):540-9. PubMed ID: 21709698
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.
Melisi D; Troiani T; Damiano V; Tortora G; Ciardiello F
Endocr Relat Cancer; 2004 Mar; 11(1):51-68. PubMed ID: 15027885
[TBL] [Abstract][Full Text] [Related]
25. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
Arnall JR; Petro R; Patel JN; Kennedy L
J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy cancer treatment during the past sixty years].
Furue H
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1404-11. PubMed ID: 14584272
[TBL] [Abstract][Full Text] [Related]
27. Principles of current cancer chemotherapy.
Wiemann MC; Calabresi P
Compr Ther; 1983 Mar; 9(3):46-52. PubMed ID: 6839689
[TBL] [Abstract][Full Text] [Related]
28. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Chalmers AJ
Anticancer Agents Med Chem; 2010 Sep; 10(7):520-33. PubMed ID: 20879987
[TBL] [Abstract][Full Text] [Related]
29. Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate.
Afrashteh Nour M; Hajiasgharzadeh K; Kheradmand F; Asadzadeh Z; Bolandi N; Baradaran B
Life Sci; 2021 Aug; 278():119557. PubMed ID: 33930371
[TBL] [Abstract][Full Text] [Related]
30. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
Bates D; Eastman A
Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987
[TBL] [Abstract][Full Text] [Related]
31. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
32. Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.
Chan KS
Clin Cancer Res; 2016 Feb; 22(4):802-6. PubMed ID: 26671994
[TBL] [Abstract][Full Text] [Related]
33. HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.
Järvinen TA; Liu ET
Comb Chem High Throughput Screen; 2003 Aug; 6(5):455-70. PubMed ID: 12871052
[TBL] [Abstract][Full Text] [Related]
34. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
Chamariya R; Suvarna V
Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
[TBL] [Abstract][Full Text] [Related]
35. Improving the cancer chemotherapy use process.
Fischer DS; Alfano S; Knobf MT; Donovan C; Beaulieu N
J Clin Oncol; 1996 Dec; 14(12):3148-55. PubMed ID: 8955661
[TBL] [Abstract][Full Text] [Related]
36. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
[TBL] [Abstract][Full Text] [Related]
37. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
38. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
39. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
40. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.
Wennier ST; Liu J; McFadden G
Curr Pharm Biotechnol; 2012 Jul; 13(9):1817-33. PubMed ID: 21740354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
